Literature DB >> 843115

Multicentre trial of naproxen and phenylbutazone in acute gout.

R A Sturge, J T Scott, E B Hamilton, S P Liyanage, A S Dixon, J Davies, C Engler.   

Abstract

Naproxen 750 mg as a single dose followed by 250 mg three times daily has been compared with phenylbutazone 200 mg four times daily for 48 hours followed by 200 mg three times daily for treatment of acute gout in an open study on 41 patients. The drugs were equally effective with few and relatively mild side effects. Naproxen is a useful alternative agent for the treatment of acute gout.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 843115      PMCID： PMC1006635          DOI： 10.1136/ard.36.1.80

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  19 in total

1.  A double-blind cross-over study of naproxen and indomethacin in patients with rheumatoid arthritis.

Authors:  O Kogstad
Journal:  Scand J Rheumatol Suppl       Date:  1973

2.  Naproxen. A new non-hormonal anti-inflammatory agent. Studies in rheumatoid arthritis.

Authors:  H F Hill; A G Hill; A G Mowat; B M Ansell; J A Mathews; M H Seifert; J M Gumpel; G A Christie
Journal:  Ann Rheum Dis       Date:  1974-01       Impact factor: 19.103

3.  Measurement of clinical response to anti-inflammatory drug therapy in rheumatoid arthritis.

Authors:  S D Deodhar; W C Dick; R Hodgkinson; W W Buchanan
Journal:  Q J Med       Date:  1973-04

4.  A phlogistic function of prostaglandin E1 in urate crystal inflammation.

Authors:  C W Denko
Journal:  J Rheumatol       Date:  1974-06       Impact factor: 4.666

5.  Comparison of indomethacin and phenylbutazone in acute gout.

Authors:  C J Smyth; J S Percy
Journal:  Ann Rheum Dis       Date:  1973-07       Impact factor: 19.103

6.  Acute gouty arthritis and response to colchicine in the virtual absence of synovial-fluid leukocytes.

Authors:  R W Ortel; D S Newcombe
Journal:  N Engl J Med       Date:  1974-06-13       Impact factor: 91.245

7.  Urate crystal arthritis in animals lacking Hageman factor.

Authors:  I Spilberg
Journal:  Arthritis Rheum       Date:  1974 Mar-Apr

8.  A rapid spectrophotometric assay for prostaglandin synthetase: application to the study of non-steroidal antiinflammatory agents.

Authors:  C Takeguchi; C J Sih
Journal:  Prostaglandins       Date:  1972-09

9.  Quantitative determination of prostaglandins and malondialdehyde formed by the arachidonate oxygenase (prostaglandin synthetase) system of bovine seminal vesicle.

Authors:  R J Flower; H S Cheung; D W Cushman
Journal:  Prostaglandins       Date:  1973-09

10.  The treatment of acute gout with naproxen.

Authors:  R F Willkens; J B Case; F J Huix
Journal:  J Clin Pharmacol       Date:  1975-04       Impact factor: 3.126
View more
  10 in total

1.  Matching the Drug to the Patient: The rational use of antiarthritic drugs.

Authors:  P Lee
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

Review 2.  New knowledge of the pathogenesis of gout.

Authors:  J T Scott
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1978

3.  2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Authors:  Dinesh Khanna; Puja P Khanna; John D Fitzgerald; Manjit K Singh; Sangmee Bae; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

4.  Clinical trials: proposal for an international coding system (ICS).

Authors:  N Bellamy
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

Review 5.  Non-steroidal anti-inflammatory drugs for acute gout.

Authors:  Caroline Mpg van Durme; Mihir D Wechalekar; Robert Bm Landewé; Jordi Pardo Pardo; Sheila Cyril; Désirée van der Heijde; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2021-12-09

6.  Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis.

Authors:  R C Butler; D H Goddard; C S Higgens; P Hollingworth; C T Pease; M A Stodell; J T Scott
Journal:  Br J Clin Pharmacol       Date:  1985-11       Impact factor: 4.335

Review 7.  Systemic corticosteroids for acute gout.

Authors:  H J E M Janssens; P L B J Lucassen; F A Van de Laar; M Janssen; E H Van de Lisdonk
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

Review 8.  Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-10       Impact factor: 9.546

9.  Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.

Authors:  Francisca Sivera; Mariano Andrés; Loreto Carmona; Alison S R Kydd; John Moi; Rakhi Seth; Melonie Sriranganathan; Caroline van Durme; Irene van Echteld; Ophir Vinik; Mihir D Wechalekar; Daniel Aletaha; Claire Bombardier; Rachelle Buchbinder; Christopher J Edwards; Robert B Landewé; Johannes W Bijlsma; Jaime C Branco; Rubén Burgos-Vargas; Anca I Catrina; Dirk Elewaut; Antonio J L Ferrari; Patrick Kiely; Burkhard F Leeb; Carlomaurizio Montecucco; Ulf Müller-Ladner; Mikkel Ostergaard; Jane Zochling; Louise Falzon; Désirée M van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-07-18       Impact factor: 19.103

10.  Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis.

Authors:  Mengtao Li; Chen Yu; Xiaofeng Zeng
Journal:  BMJ Open       Date:  2020-09-10       Impact factor: 2.692
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.